Clinical Information

Hypersensitivity pneumonitis (HP) is a complex inflammatory lung disease triggered by repeated inhalation of various organic and inorganic antigens in susceptible individuals.(1-3) The condition presents significant diagnostic challenges due to its diverse clinical presentations, variable disease progression, and overlap with other interstitial lung diseases.(1,3-5) The 2020 American Thoracic Society and Japanese Respiratory Society, and Asociacion Latinoamericana del Torax (ATS/JRS/ALAT) Clinical Practice Guideline emphasizes that HP diagnosis requires a comprehensive multidisciplinary approach integrating clinical history, exposure assessment, radiological findings, and when necessary, histopathological examination.(1,5) Currently, no single test is sufficient for definitive diagnosis of HP.

Serum IgG testing serves as one component of the diagnostic workup for HP, particularly in identifying specific antigenic exposures. However, studies demonstrate significant limitations in the diagnostic performance of serum IgG testing alone.(1,3,4) The clinical validity of HP antibody assays is enhanced when used within a structured diagnostic framework.(1) Multidisciplinary team meetings have shown improved diagnostic agreement in diffuse parenchymal lung diseases, highlighting the importance of integrating serological findings with other clinical data rather than relying on laboratory results in isolation.(2) Contemporary understanding of HP recognizes an expanding spectrum of causative agents beyond traditional organic dust. Occupational causes encompass diverse antigens including microbial agents, animal proteins, and chemical compounds.(6,7). The use of multi-analyte antibody panels can help identify specific antigenic exposures, particularly in occupational settings, though the absence of detectable antibodies does not exclude HP diagnosis.

Recent research has identified distinct clinical phenotypes in HP that may influence the interpretation of serological testing.(8) The relationship between specific exposures and clinical presentations varies considerably, with some patients developing disease despite minimal apparent exposure while others with significant exposure remain asymptomatic. The pathogenesis of HP involves complex immune mechanisms beyond simple antibody-mediated responses, including T-cell activation and inflammatory cascades.(1,3) This complexity underscores why serological testing alone cannot be used to establish or exclude the diagnosis of HP.(3, 4) In addition, reference intervals for the analytes tested do vary between laboratories, even when the same instrument and reagents are used.(9-10)

The panel's clinical validity is established through its ability to identify specific antigenic exposures and immune responses associated with HP, while requiring integration with comprehensive clinical assessment for optimal diagnostic accuracy. Healthcare professionals should utilize these assays as one component of a comprehensive diagnostic evaluation, maintaining awareness of their limitations while leveraging their potential to identify relevant exposures and guide further clinical investigation.